Back

Real-world outcomes of microaxial flow pump use in cardiogenic shock: comparison with the DanGer Shock cohort

20 March 2026 (09:40 - 10:40)
Organised by: Logo
Congress Presentation Part of: Cardiogenic shock, physiology, and kidney injury Shock ACVC Premium Access ESC Acute CardioVascular Care 2026 Association for Acute CardioVascular Care (ACVC)

About the speaker

Photo
Doctor Nazar Ilchyshyn

Hospital Garcia de Orta, Almada (Portugal)

8 More presentations in this session

Presentation thumbnail
Anemia and acute kidney injury in patients undergoing staged percutaneous coronary intervention for myocardial infarction
Doctor A. Galas (Warsaw, PL)
Abstract
Presentation thumbnail
Decoupling lactate from DO2 VO2 rethinking the physiology of stress hyperlactatemia during cardiac failure
Professor C. Vandenbriele (London, GB)
Abstract
Presentation thumbnail
Butyrate infusion improves cardiac performance without aggravating myocardial injury in a porcine model of myocardial ischemic reperfusion
Mr J. Schuetz (Aarhus N, DK)
Abstract
Presentation thumbnail
Impact and predictors of acute kidney injury in cardiogenic shock following acute myocardial infarction
Doctor A. Freund (Leipzig, DE)
Abstract
Presentation thumbnail
Predictors of contrast induced nephropathy in patients with normal renal function undergoing percutaneous coronary intervention - ADAPH score
Doctor F. Rodrigues Santos (Viseu, PT)
Abstract

Access the full session

Session thumbnail
Cardiogenic shock, physiology, and kidney injury

The Event

Event poster

ESC Acute CardioVascular Care 2026

20 March 2026 09:40 CET
You may be interested in
thumbnail
Congress Presentation
Microaxial pump support in cardiogenic shock and high-risk PCI: experience from a Portuguese level II centre
thumbnail
Congress Presentation
Infarct-related cardiogenic shock with and without cardiac arrest: Insights from randomized trials of mechanical circulatory support
thumbnail
Congress Presentation
Predicting fast recovery in infarct related cardiogenic shock: insights from the DanGer Shock trial

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources